To be conducted within the UCSF Helen Diller Family Comprehensive Cancer Center, the Phase II trial will investigate PEGPH20 in combination with gemcitabine and nab-paclitaxel (ABRAXANE) in patients
TD-8954 is being evaluated for potential use in the treatment of gastrointestinal motility disorders, including enteral feeding intolerance (EFI). Currently, TD-8954 is in Phase II clinical development having
Breo Ellipta is a fixed-dose combination (FDC) of the inhaled corticosteroid (ICS) fluticasone furoate and the long-acting beta2-agonist (LABA) vilanterol. In Canada two strengths 100/25mcg and 200/25mcg of
Additionally, the European Medicines Agency (EMA) has granted orphan designation for the same product to treat perinatal asphyxia, an alternate term that describes the same condition as NHIE,
The deal will see AstraZeneca acquire exclusive global rights from Heptares to develop, manufacture and commercialise the adenosine A2A receptor antagonist, HTL-1071, a small molecule immuno-oncology candidate, and
The CMA has issued a statement of objections to these two firms alleging that they have breached the UK and EU competition law. The drug, which is indicated
The company is focused on the development of new therapies for combating human immunodeficiency virus (HIV) infection. The primary end point of the Phase III trial is to
The first license agreement is with the Indiana University Research and Technology Corporation (IURTC) and the second is with the IURTC and the University of Alabama at Birmingham
Viberzi, an orally active compound indicated to treat IBS-D in men and women, has mixed opioid receptor activity and is a mu receptor agonist, a delta receptor antagonist
FAP affects an estimated one in 10,000 people across the world and is associated with a near 100% risk of colon cancer if untreated. Additionally, the company announced
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.